These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20121659)

  • 1. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
    Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
    Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder.
    Cardozo L; Khullar V; El-Tahtawy A; Guan Z; Malhotra B; Staskin D
    BMC Urol; 2010 Aug; 10():14. PubMed ID: 20723260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
    Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
    Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.